AbbVie is conducting a study titled ‘SUNRISE-UC’ to evaluate the effectiveness and safety of Risankizumab in patients with moderate to severe ulcerative colitis. This real-world study aims to assess ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a study titled ‘Prospective ...

Risankizumab was shown to produce rapid and durable clearing of skin lesions in a phase 1 trial involving patients with moderate-to-severe psoriasis. 15 This 48-week phase 2 trial of risankizumab ...

At week 16, 55.9% of the risankizumab group and 5.1% of the apremilast group achieved PASI 90. 75.4% of risankizumab-treated patients vs. 18.4% of apremilast-treated patients achieved sPGA 0/1 by ...

TOPLINE: Risankizumab was well tolerated and demonstrated sustained effectiveness and drug survival in patients with moderate-to-severe psoriasis over a period of 4 years. Obesity, difficult-to ...

Risankizumab is an interleukin (IL)-23 p19 inhibitor that was approved for the treatment of adults with moderately to severely active Crohn's disease in June 2022, while ustekinumab is an IL-12/23 ...

Assuming that risankizumab would reduce the risk of asthma worsening by 40%, we calculated that a total of 89 events and 100 patients per group would be required to provide the trial with 87% ...

In the risankizumab arm, 84.7% of patients achieved PASI 75 at week 16 vs 18.8% of patients in the apremilast arm (secondary endpoint; P <.001).

Risankizumab, an interleukin-23 (IL-23) inhibitor, is currently marketed under the trade name Skyrizi and is approved for the treatment of active psoriatic arthritis, moderately to severely active ...

The FDA approved risankizumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, in March 2019 for the treatment PsA in adults.

Risankizumab appeared to worsen severe asthma symptoms compared with placebo, according to results of a randomized phase 2a study published in The New England Journal of Medicine. Risankizumab ...

Risankizumab is approved in the United States for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a humanized ...